2006
THE INFLUENCE OF DONOR-SPECIFIC ANTIBODIES IN KIDNEY TRANSPLANT RECIPIENTS WITH POSITIVE CDC B-CELL/FLOW CYTOMETRY CROSSMATCH TREATED WITH LOW DOSE INTRAVENOUS IMMUNOGLOBULIN AND ANTI-THYMOCYTE GLOBULIN INDUCTION THERAPY.
Moss A, Heilman R, Mazur M, Chakkera H, Wozniak E, Post D, Mulligan D, Reddy K. THE INFLUENCE OF DONOR-SPECIFIC ANTIBODIES IN KIDNEY TRANSPLANT RECIPIENTS WITH POSITIVE CDC B-CELL/FLOW CYTOMETRY CROSSMATCH TREATED WITH LOW DOSE INTRAVENOUS IMMUNOGLOBULIN AND ANTI-THYMOCYTE GLOBULIN INDUCTION THERAPY. Transplantation 2006, 82: 292. DOI: 10.1097/00007890-200607152-00679.Peer-Reviewed Original ResearchAnti-thymocyte globulin induction therapyLow-dose intravenous immunoglobulinDose intravenous immunoglobulinFlow cytometry crossmatchDonor-specific antibodiesKidney transplant recipientsCytometry crossmatchInduction therapyIntravenous immunoglobulinTransplant recipientsCrossmatchTherapyImmunoglobulinRecipientsAntibodies
1995
Monitoring of allograft recipients for the development of HLA‐specific antibodies: Elimination of OKT3 as a complicating factor
Mulligan D, Gentry L, Dombrausky L, Klintmalm G, Nikaein A. Monitoring of allograft recipients for the development of HLA‐specific antibodies: Elimination of OKT3 as a complicating factor. Clinical Transplantation 1995, 9: 438-441. PMID: 8645885, DOI: 10.1111/j.1399-0012.1995.tb00363.x.Peer-Reviewed Original ResearchConceptsOKT3 MoAbPatient seraPanel reactive antibody (PRA) assayPositive reactivityAnti-HLA antibodiesHLA-specific antibodiesOKT3 monoclonal antibodyFalse-positive reactivityMismanagement of patientsAllograft recipientsHumoral rejectionTransplant recipientsAntibody assaysRabbit antimouse immunoglobulinAntibody developmentMonoclonal antibodiesMoAbSerumAntibodiesAntimouse immunoglobulinRecipientsComplicating factorsOKT3PatientsImmunoglobulin